Vital Therapies (VTL) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Canaccord Genuity Raises Price Target as Vital Therapies (VTL) Expects Enrollment in VTL-308 Phase 3 by 1H16
March 9, 2016 9:46 AM ESTCanaccord Genuity reiterated a Buy rating on Vital Therapies (NASDAQ: VTL), and raised the price target to $10.00 (from $8.00), as Vital expects to enroll the first patient in the VTL-308 Phase 3 by 1H16. Canaccord views the initiation of a new Phase 3 as a... More
